Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
Biodexa Pharmaceuticals (Nasdaq: BDRX), a clinical stage biopharmaceutical company, has announced its upcoming presentation at the Emerging Growth Conference on February 19, 2025. The company's CEO/CFO, Stephen Stamp, will deliver a live, interactive presentation at 09:40 AM Eastern time for 30 minutes.
The event offers shareholders and the investment community an opportunity to interact with Mr. Stamp in real-time. Participants can submit questions in advance to Questions@EmergingGrowth.com or during the live session. For those unable to attend live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.
Registration is required for attendance and updates through the provided webcast link. Biodexa focuses on developing innovative products for diseases with unmet medical needs.
Biodexa Pharmaceuticals (Nasdaq: BDRX), una compagnia biofarmaceutica in fase clinica, ha annunciato la sua prossima presentazione alla Emerging Growth Conference il 19 febbraio 2025. L'amministratore delegato e CFO dell'azienda, Stephen Stamp, terrà una presentazione interattiva dal vivo alle 09:40 AM ora orientale per 30 minuti.
L'evento offre agli azionisti e alla comunità degli investimenti l'opportunità di interagire con il signor Stamp in tempo reale. I partecipanti possono inviare domande in anticipo a Questions@EmergingGrowth.com o durante la sessione dal vivo. Per coloro che non possono partecipare dal vivo, sarà disponibile una registrazione dell'evento su EmergingGrowth.com e sul canale YouTube di Emerging Growth.
È necessaria la registrazione per partecipare e ricevere aggiornamenti tramite il link fornito per la trasmissione web. Biodexa si concentra sullo sviluppo di prodotti innovativi per malattie con esigenze mediche insoddisfatte.
Biodexa Pharmaceuticals (Nasdaq: BDRX), una empresa biofarmacéutica en etapa clínica, ha anunciado su próxima presentación en la Emerging Growth Conference el 19 de febrero de 2025. El CEO/CFO de la compañía, Stephen Stamp, ofrecerá una presentación interactiva en vivo a las 09:40 AM hora del este durante 30 minutos.
El evento brinda a los accionistas y a la comunidad de inversión la oportunidad de interactuar con el Sr. Stamp en tiempo real. Los participantes pueden enviar preguntas con anticipación a Questions@EmergingGrowth.com o durante la sesión en vivo. Para aquellos que no puedan asistir en vivo, habrá una grabación disponible en EmergingGrowth.com y en el canal de YouTube de Emerging Growth.
Se requiere registro para asistir y recibir actualizaciones a través del enlace de transmisión web proporcionado. Biodexa se enfoca en desarrollar productos innovadores para enfermedades con necesidades médicas no satisfechas.
바이오덱사 제약 (Nasdaq: BDRX)은 임상 단계의 생명공학 기업으로, Emerging Growth Conference에서 2025년 2월 19일에 발표할 예정이라고 발표했습니다. 회사의 CEO/CFO인 Stephen Stamp는 동부 표준시 기준으로 오전 09:40에 30분 동안 라이브 인터랙티브 발표를 진행할 것입니다.
이번 행사는 주주와 투자 커뮤니티가 Stamp 씨와 실시간으로 소통할 수 있는 기회를 제공합니다. 참가자들은 사전에 Questions@EmergingGrowth.com으로 질문을 제출하거나 라이브 세션 중에 질문할 수 있습니다. 라이브 참석이 불가능한 경우, EmergingGrowth.com과 Emerging Growth YouTube 채널에서 아카이브된 웹캐스트를 이용할 수 있습니다.
참석을 위해서는 등록이 필요하며 제공된 웹캐스트 링크를 통해 업데이트를 받을 수 있습니다. 바이오덱사는 충족되지 않은 의료 요구가 있는 질병을 위한 혁신적인 제품 개발에 집중하고 있습니다.
Biodexa Pharmaceuticals (Nasdaq: BDRX), une entreprise biopharmaceutique en phase clinique, a annoncé sa prochaine présentation à la Emerging Growth Conference le 19 février 2025. Le PDG/CFO de l'entreprise, Stephen Stamp, fera une présentation interactive en direct à 09h40, heure de l'Est, pendant 30 minutes.
L'événement offre aux actionnaires et à la communauté des investisseurs l'occasion d'interagir en temps réel avec M. Stamp. Les participants peuvent soumettre des questions à l'avance à Questions@EmergingGrowth.com ou durant la session en direct. Pour ceux qui ne peuvent pas assister en direct, un webinaire archivé sera disponible sur EmergingGrowth.com et sur la chaîne YouTube d'Emerging Growth.
Une inscription est requise pour assister et recevoir des mises à jour via le lien de webinaire fourni. Biodexa se concentre sur le développement de produits innovants pour des maladies ayant des besoins médicaux non satisfaits.
Biodexa Pharmaceuticals (Nasdaq: BDRX), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine bevorstehende Präsentation auf der Emerging Growth Conference am 19. Februar 2025 angekündigt. Der CEO/CFO des Unternehmens, Stephen Stamp, wird eine interaktive Live-Präsentation um 09:40 Uhr Eastern Time für 30 Minuten halten.
Die Veranstaltung bietet Aktionären und der Investmentgemeinschaft die Möglichkeit, in Echtzeit mit Herrn Stamp zu interagieren. Teilnehmer können im Voraus Fragen an Questions@EmergingGrowth.com senden oder während der Live-Sitzung Fragen stellen. Für diejenigen, die nicht live teilnehmen können, wird eine archivierte Webcast auf EmergingGrowth.com und dem Emerging Growth YouTube-Kanal verfügbar sein.
Eine Registrierung ist erforderlich, um an der Veranstaltung teilzunehmen und Updates über den bereitgestellten Webcast-Link zu erhalten. Biodexa konzentriert sich auf die Entwicklung innovativer Produkte für Krankheiten mit unerfüllten medizinischen Bedürfnissen.
- None.
- None.
February 13, 2025
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025
Biodexa Pharmaceuticals PLC invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference
Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 19, 2025.
The live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s CEO / CFO, Stephen Stamp in real time.
Mr Stamp will make a presentation and may subsequently open the floor for questions. Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event and Mr Stamp will do his best to get through as many of them as possible.
Biodexa will be presenting at 09:40 AM Eastern time for 30 minutes.
Please register here to ensure you are able to attend the conference and receive any updates that are released.
https://goto.webcasts.com/starthere.jsp?ei=1696664&tp_key=a17d7ff4c2&sti=bdrx
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference. We will release a link to that after the event.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Blader Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications.
eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signaling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.
Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
FAQ
When is Biodexa Pharmaceuticals (BDRX) presenting at the Emerging Growth Conference?
How can investors participate in Biodexa's (BDRX) Emerging Growth Conference presentation?
What will be discussed at Biodexa's (BDRX) February 2025 Emerging Growth Conference?
How can investors access Biodexa's (BDRX) presentation if they miss the live event?
What is the duration of Biodexa's (BDRX) presentation at the February 2025 Emerging Growth Conference?
